Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective

The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Haluzík, Martin, Flekač, Milan, Lengyel, Csaba, Taybani, Zoltán, Guja, Cristian, Mihai, Bogdan-Mircea, Cerghizan, Anca, Martinka, Emil, Kovacs, Gabor, Kempler, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Practical Approach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136377/
https://www.ncbi.nlm.nih.gov/pubmed/32144742
http://dx.doi.org/10.1007/s13300-020-00777-2
_version_ 1783518234963607552
author Haluzík, Martin
Flekač, Milan
Lengyel, Csaba
Taybani, Zoltán
Guja, Cristian
Mihai, Bogdan-Mircea
Cerghizan, Anca
Martinka, Emil
Kovacs, Gabor
Kempler, Péter
author_facet Haluzík, Martin
Flekač, Milan
Lengyel, Csaba
Taybani, Zoltán
Guja, Cristian
Mihai, Bogdan-Mircea
Cerghizan, Anca
Martinka, Emil
Kovacs, Gabor
Kempler, Péter
author_sort Haluzík, Martin
collection PubMed
description The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting.
format Online
Article
Text
id pubmed-7136377
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71363772020-04-09 Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective Haluzík, Martin Flekač, Milan Lengyel, Csaba Taybani, Zoltán Guja, Cristian Mihai, Bogdan-Mircea Cerghizan, Anca Martinka, Emil Kovacs, Gabor Kempler, Péter Diabetes Ther Practical Approach The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting. Springer Healthcare 2020-03-06 2020-04 /pmc/articles/PMC7136377/ /pubmed/32144742 http://dx.doi.org/10.1007/s13300-020-00777-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Practical Approach
Haluzík, Martin
Flekač, Milan
Lengyel, Csaba
Taybani, Zoltán
Guja, Cristian
Mihai, Bogdan-Mircea
Cerghizan, Anca
Martinka, Emil
Kovacs, Gabor
Kempler, Péter
Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title_full Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title_fullStr Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title_full_unstemmed Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title_short Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
title_sort expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 u/ml and lixisenatide: a central/eastern european perspective
topic Practical Approach
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136377/
https://www.ncbi.nlm.nih.gov/pubmed/32144742
http://dx.doi.org/10.1007/s13300-020-00777-2
work_keys_str_mv AT haluzikmartin expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT flekacmilan expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT lengyelcsaba expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT taybanizoltan expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT gujacristian expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT mihaibogdanmircea expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT cerghizananca expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT martinkaemil expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT kovacsgabor expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective
AT kemplerpeter expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective

Ejemplares similares